Sentinel lymph node biopsy for lentigo maligna melanoma under local anaesthesia

Abstract

AbstractBackgroundLentigo maligna melanoma is mainly localized in the head and neck region in elderly patients. Due to its slow horizontal growth, it has a good prognosis compared to other melanoma subtypes, but specific data are rare.ObjectivesThe aim of this study was to investigate sentinel lymph node biopsy in lentigo maligna melanoma under local anaesthesia and to discuss the benefit.MethodsInvestigation of patients with lentigo maligna melanoma and tumour thickness ≥1 mm treated at the Department of Dermatology, University Medical Centre Tuebingen, between January 2008 and October 2019.ResultsIn total, 204 patients (126 SLNB, 78 non‐SLNB) with a median age of 75.7 years (SLNB: 73.3 years, non‐SLNB: 79.7 years) could be included. Sixteen of 126 (12.7%) sentinel lymph nodes were positive. Five‐year overall survival was 87.9% (88.5% SLNB; 87.4% non‐SLNB) and 5‐year distant metastasis‐free survival was 85.8% (85.4% SLNB; 86.7% non‐SLNB). There was no significant difference for distant metastasis‐free survival (p = 0.861) and overall survival (p = 0.247) between patients with and without sentinel lymph node biopsy.ConclusionsSentinel lymph node biopsy in lentigo maligna melanoma under local anaesthesia is a safe and simple method, even in very old patients. However, LMM has a very good 5‐year overall survival. In high‐risk patients with high tumour thickness and/or ulceration, adjuvant immunotherapy can now be offered without the need to perform this procedure.